‘Surprised and Disappointed’ Santhera To Fight EU’s DMD Rejection

Santhera has vowed to appeal against this week’s recommendation by the European Medicines Agency that the company’s application to extend Raxone’s indication to cover DMD be rejected. The agency recommended EU approval for four other drug applications seeking extended indications.

Businessman looking through a magnifying glass to documents
Santhera wants a re-examination of the EMA's decision on Raxone for Duchenne

Santhera Pharmaceuticals is “surprised and disappointed” that EU regulators have said that its drug, Raxone (idebenone), should not be approved in the EU for the additional indication of Duchenne muscular dystrophy (DMD). The company’s share price fell sharply on the news.

Santhera is planning to appeal the negative opinion from the European Medicines Agency’s key scientific committee, the CHMP. It says...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approvals

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>